resiquimod has been researched along with Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Im, SA; Lee, CK; Lee, M; Lee, YR; Park, CS; Song, S | 1 |
| Anz, D; Bourquin, C; Endres, S; Heidegger, S; Hotz, C; Noerenberg, D; Roetzer, LC; Sandholzer, N; Storch, B; Voelkl, A; Wurzenberger, C | 1 |
2 other study(ies) available for resiquimod and Carcinoma
| Article | Year |
|---|---|
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dendritic Cells; Imidazoles; Immunologic Factors; Macrophages; Male; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Myeloid Progenitor Cells; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2014 |
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Topics: Animals; Carcinoma; Cells, Cultured; Colonic Neoplasms; Cytokines; Dendritic Cells; Drug Screening Assays, Antitumor; Female; Imidazoles; Immune Tolerance; Interferon-alpha; Interleukin-1 Receptor-Associated Kinases; Interleukin-12; Interleukin-6; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Toll-Like Receptor 7; Tumor Escape | 2011 |